Macquarie Group’s Apogee Therapeutics APGE Stock Holding History

Macquarie Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-305	Closed	-$12K	–	1664
2024 Q2	$12K	Buy	+305	New	+$14.8K	﹤0.01%	1650

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Macquarie Group's APGE Position: Q3 2024 in Review

Macquarie Group sold out of Apogee Therapeutics (APGE) in Q3 2024, closing a stake of 305 shares — an estimated $12K sold.

Macquarie Group first reported a position in APGE in Q2 2024 and held it in 1 quarter. The position peaked at $12K in Q2 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q3 2024.

Macquarie Group reported no remaining Apogee Therapeutics position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 305 Apogee Therapeutics shares in Q3 2024, an estimated $12K.
Macquarie Group first reported a position in Apogee Therapeutics in Q2 2024 and held it in 1 quarter.
Macquarie Group's Apogee Therapeutics position peaked at $12K in Q2 2024.
139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.